acetylsalicylic acid
Drugaspirin 50 mg/d to be taken after dinner (in nonfasting conditions)
NCT Number: NCT06068439
This is a multicenter, randomized, placebo-controlled study to evaluate the effectiveness and safety of low-dose aspirin (50 mg/day) in renal and cardiac function protection in people with diabetic nephropathy.
Trial opening soon.
Get Notified18 year–70 year
All sexes
Interventional
Phase 2 / Phase 3
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
aspirin 50 mg/d to be taken after dinner (in nonfasting conditions)
Placebo 50 mg/d to be taken after dinner (in nonfasting conditions)
Time frame: 3YEARS
The aim of the study is to evaluate the decline of renal function, as assessed by absolute change in eGFR, calculated as the difference between eGFR at 3 years and baseline eGFR, in T2DM patients receiving low-dose aspirin (50 mg/d) or lacebo.
Time frame: 3YEARS
The rapid decline in renal function, defined as a reduction of eGFR ≥5 mL/min at 1 year
Time frame: 3YEARS
Change of renal function class (from G1 to G2, from G2 to G3a, and so on) at 3 years, dialysis, or transplantation
Second Affiliated Hospital, School of Medicine, Zhejiang University
Other
A Phase III Multi-center Randomized Placebo-controlled Study of the Protective Effect of Low-dose Aspirin on Renal Function in Patients With Early Diabetic
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07644520
Diabetic Nephropathy Type 2
View Trial DetailsNCT07459946
Chronic Renal Failure/ Kidney Disease, Diabetic Nephropathy Type 2
View Trial DetailsNCT06690034
Diabetic Nephropathy Type 2
View Trial DetailsNCT04573920
Alport Syndrome, Autoimmune Diseases
Glendale, California, United States
View Trial Details